Revian has secured up to $13 million in new financing to accelerate the commercialization of its FDA-cleared hair regrowth light therapy system. The funding round, led by international tech investment firm Flashpoint, combines equity and growth debt and will support commercial scale-up, new product development, and the launch of global operations. Flashpoint, which manages approximately $600 million in assets, invests globally across high-growth technology sectors.
Revian develops an at-home hair regrowth device that uses a patented dual-wavelength red-light system to trigger nitric oxide production. The company says this biological response inhibits 5-alpha reductase to reduce DHT levels, increases scalp microcirculation, and reduces inflammation by targeting multiple pathways known to drive follicle miniaturization and hair loss. Revian positions its system as both a clinically meaningful adjunct to existing treatments and, in some cases, a non-pharmacological alternative.
The company’s RED device integrates with a mobile platform that allows physicians to monitor patient compliance in real time, aiming to improve long-term clinical outcomes and accountability. Revian has emphasized the importance of this connected-care model as it expands its physician-led footprint in the United States and internationally.
The financing arrives as Revian reports increasing demand from medical practices and continued momentum following clinical studies that demonstrated measurable improvements in hair growth outcomes. The company intends to leverage Flashpoint’s investment to enter new markets while expanding its operational infrastructure.
Tungsten Advisors served as the sole placement agent for the transaction.
Revian’s system is FDA-cleared for the treatment of androgenetic alopecia. The lightweight, wireless cap is indicated for men with Norwood-Hamilton IIa-V classifications and for women with Ludwig-Savin I-1 to II-4, II1, II2, or certain frontal hair loss patterns, all within Fitzpatrick Skin Types I-IV. The company describes its dual-wavelength technology as providing deeper skin penetration and broad scalp coverage, contributing to strong clinical trial performance relative to other non-invasive hair restoration options.
Revian is an operating subsidiary of KNOW Bio and focuses on medical technologies that stimulate natural biological processes with precision light. The company says its goal is to deliver clinically validated regenerative treatments that can be used conveniently at home while maintaining strong collaboration with healthcare providers.
Flashpoint, based in London with offices in New York and Tel Aviv, manages seven funds across growth-oriented strategies, including Venture Growth, Growth Debt, and Direct Secondary. Its Growth Debt arm has committed more than $70 million to rapidly scaling technology companies and continues to deploy capital from its second fund, which closed in June 2025.
KEY QUOTES
“We’ve gained tremendous conviction in Revian through the depth of their scientific documentation and the rigor of their clinical trials, as well as their cutting-edge digital technology, which clearly set them apart in the market. Meeting and collaborating with the leadership team has only reinforced our confidence in John’s ability to bring the vision for Revian to life, and we’re genuinely excited to be part of this journey.”
Denis Mosolov, Managing Partner, Flashpoint Growth Debt
“This financing enables us to meet accelerating demand from medical practices nationwide while laying the foundation for our global expansion. We’ve demonstrated strong clinical results and a scalable physician-led model. Flashpoint’s partnership allows us to extend that success to new markets and patients worldwide.”
John Oakley, Chief Executive Officer, Revian
